Scholarlink

Background <p>Opioid tapering has increased in recent years; however, evidence regarding its safety profile is lacking.</p> Objective <p>To examine the relationships between opioid tapering and subsequent overdose (OD), opioid use disorder (OUD), and all-cause mortality among older adults on long-term opioid therapy (LTOT).</p> Design <p>Nested case–control design.</p> Participants <p>A cohort of older (≥ 65 years) Medicare beneficiaries with chronic non-cancer pain who were on LTOT was identified from 2012–2020 5% national Medicare claims data.</p> Main Measures <p>The key independent variable was rate of opioid tapering, operationalized as a monthly dose change percentage with four levels: steady dose (± 10% dose change), slow tapering (10–40% dose reduction), rapid tapering (&gt; 40% dose reduction), and dose escalation (&gt; 10% dose increase). The outcome variables were OD, OUD, and all-cause mortality. Conditional logistic regression was conducted on matched samples to evaluate the associations between opioid tapering and the outcomes.</p> Key Results <p>Among a cohort of 82,295, 1333 cases of OD, 4933 cases of OUD, and 5971 cases of all-cause mortality were identified. In primary analyses, after controlling for all covariates, compared with steady dose, the odds of OD were significantly lower (aOR = 0.74; 95% CI = 0.55–0.99) for rapid tapering and significantly higher (aOR = 2.08; 95% CI = 1.64–2.65) for dose escalation. Compared to steady dose, the odds of OUD were significantly lower (aOR = 0.53; 95% CI = 0.46–0.60) for rapid tapering and significantly higher (aOR = 1.60; 95% CI = 1.42–1.81) for dose escalation. Compared to steady dose, significantly higher odds for all-cause mortality were found among patients undergoing rapid tapering (aOR = 1.28; 95% CI = 1.14–1.44), and dose escalation (aOR = 1.51; 95% CI = 1.34–1.71). Sensitivity analyses showed that mortality outcome is sensitive to variations in cohort selections.</p> Conclusion <p>The results suggest that any opioid dose change for patients on LTOT may negatively affect all-cause mortality. Clinicians should regularly assess patients on LTOT, considering the benefits and risks of treatment that incorporate evolving evidence on dose changes.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Opioid Tapering and Opioid Overdose, Opioid Use Disorder, and Mortality Among Older Adults: A Nested Case–Control Study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年4月22日

查看全文
  • Yi Yang,
  • Prachi Prajapati,
  • Sujith Ramachandran,
  • Kaustuv Bhattacharya,
  • Shadi Bazzazzadehgan,
  • Shishir Maharjan,
  • Ike Eriator,
  • John P. Bentley

摘要

Background

Opioid tapering has increased in recent years; however, evidence regarding its safety profile is lacking.

Objective

To examine the relationships between opioid tapering and subsequent overdose (OD), opioid use disorder (OUD), and all-cause mortality among older adults on long-term opioid therapy (LTOT).

Design

Nested case–control design.

Participants

A cohort of older (≥ 65 years) Medicare beneficiaries with chronic non-cancer pain who were on LTOT was identified from 2012–2020 5% national Medicare claims data.

Main Measures

The key independent variable was rate of opioid tapering, operationalized as a monthly dose change percentage with four levels: steady dose (± 10% dose change), slow tapering (10–40% dose reduction), rapid tapering (> 40% dose reduction), and dose escalation (> 10% dose increase). The outcome variables were OD, OUD, and all-cause mortality. Conditional logistic regression was conducted on matched samples to evaluate the associations between opioid tapering and the outcomes.

Key Results

Among a cohort of 82,295, 1333 cases of OD, 4933 cases of OUD, and 5971 cases of all-cause mortality were identified. In primary analyses, after controlling for all covariates, compared with steady dose, the odds of OD were significantly lower (aOR = 0.74; 95% CI = 0.55–0.99) for rapid tapering and significantly higher (aOR = 2.08; 95% CI = 1.64–2.65) for dose escalation. Compared to steady dose, the odds of OUD were significantly lower (aOR = 0.53; 95% CI = 0.46–0.60) for rapid tapering and significantly higher (aOR = 1.60; 95% CI = 1.42–1.81) for dose escalation. Compared to steady dose, significantly higher odds for all-cause mortality were found among patients undergoing rapid tapering (aOR = 1.28; 95% CI = 1.14–1.44), and dose escalation (aOR = 1.51; 95% CI = 1.34–1.71). Sensitivity analyses showed that mortality outcome is sensitive to variations in cohort selections.

Conclusion

The results suggest that any opioid dose change for patients on LTOT may negatively affect all-cause mortality. Clinicians should regularly assess patients on LTOT, considering the benefits and risks of treatment that incorporate evolving evidence on dose changes.